Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0019829 (Hodgkin's disease)
 30,247 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Eleven patients with established Hodgkin's disease were treated with vinblastine sulfate. Each patient received from 0.15 to 0.20 mg./kg. of body weight intravenously in 10 divided doses over a five-hour period as initial therapy. All had received one or more of the more established forms of treatment before being given vinblastine. The response to treatment with vinblastine was excellent in three patients, good in one, and poor in three; there was no response in four. The longest remission was 15 months. Two of the patients were father and son. The side effects of treatment in this series included alopecia, leukopenia, and septicemia.
 ...
PMID:Clinical experience with vincaleukoblastine sulfate in the treatment of 11 patients with Hodgkin's disease. 582 97

The neurotoxicity of vincristine sulfate, a commonly used antineoplastic agent, has been well described. A literature review failed to reveal any absolute contraindications to the initial use of vincristine. We describe two patients with nodular sclerosing Hodgkin's disease in whom a rapidly progressive, but reversible, severe polyneuropathy developed when they were given a total of 4 mg of vincristine sulfate. Each was later shown to have the demyelinating form of Charcot-Marie-Tooth syndrome. This association suggests that the use of vincristine is contraindicated in patients with the demyelinating form of Charcot-Marie-Tooth syndrome.
 ...
PMID:Polyneuropathy following vincristine therapy in two patients with Charcot-Marie-Tooth syndrome. 609 32

We report the establishment of human-human hybridomas producing monoclonal antibody of predefined antigenic specificity. The U-266 human myeloma cell line was incubated in the presence of 8-azaguanine, and a rapidly growing, 8-azaguanine-resistant, hypoxanthine/amethopterin/thymidine (HAT) medium-sensitive mutant line, U-266AR1, was selected. These cells were fused with lymphoid cells from uninvolved spleens removed at staging laparotomy from patients with untreated Hodgkin's disease who had been previously sensitized to the chemical allergen 2,4-dinitrochlorobenzne. Hybrid cell cultures growing in HAT medium were screened for IgG production. Positive cultures were selected and their supernatants were tested in a solid-phase radioimmunoassay for reactivity with dinitrophenyl hapten coupled to bovine serum albumin. Cultures producing specific antibody were subcloned and expanded, and their antibody products were shown to be monoclonal by biosynthetic labeling and sodium dodecyl sulfate/polyacrylamide gel electrophoresis.
 ...
PMID:Human-human hybridomas producing monoclonal antibodies of predefined antigenic specificity. 615 46

SCAB chemotherapy streptozocin (streptozotocin) lomustine (CCNU), doxorubicin hydrochloride (Adriamycin), and bleomycin sulfate was given in monthly courses to 20 patients with Stages IIIB, IVA, and IVB previously untreated Hodgkin's disease. Complete remissions were obtained in 15 (75%) of these patients, and partial remissions in two others. Toxicity of this program was acceptable. Although this study was not a direct comparison with MOPP, SCAB would appear to be at least as effective as MOPP and offers a reasonable alternative program for the patient with advanced stage, previously untreated Hodgkin's disease.
 ...
PMID:Treatment of advanced untreated Hodgkin's disease with SCAB--an alternative to MOPP. 616 89

Vindesine (desacetyl vinblastine amide sulfate, DVA) was used in combination with CCNU (lomustine) and melphalan (Alkeran) (CAD) to treat 15 heavily pretreated patients with Hodgkin's disease in relapse. The patients were treated with up to six cycles, depending upon their response. Two patients (13%) achieved a complete remission (CR) and five (33%) patients a partial remission (PR). The major toxicity was prolonged thrombocytopenia, which was decreased by a reduction in the initial drug doses for patients who had received extensive prior chemotherapy and radiotherapy (RT). The CAD regimen was then alternated with nitrogen mustard or cyclophosphamide, vincristine, procarbazine, and prednisone (MOPP, C-MOPP) and doxorubicin (Adriamycin), bleomycin, and vinblastine (ABV) for a total of nine cycles in 25 patients with Hodgkin's disease in relapse with somewhat more favorable prognostic features. Two patients also received low-dose RT to areas of bulky nodal disease. Eleven patients (44%) achieved a CR and seven (28%) a PR. Of the 11 CR patients, six remain in remission. The serious toxicity was comparable to that seen with other combination chemotherapy regimens. These results indicated that the CAD/MOPP/ABVD regimen is as active as other so-called 'salvage' regimens for Hodgkin's disease in relapse, and suggest that it might be useful for newly diagnosed Hodgkin's disease.
 ...
PMID:Combination chemotherapy for the treatment of Hodgkin's disease in relapse. Results with lomustine (CCNU), melphalan (Alkeran), and vindesine (DVA) alone (CAD) and in alternation with MOPP and doxorubicin (Adriamycin), bleomycin, and vinblastine (ABV). 619 13

Ten patients with Hodgkin's disease were examined before and after each administration of vincristine sulfate (2 intravenous injections of 1.4 mg/m2 of body surface during the first week of each month for 3 months). The motor conduction velocity of the peroneal nerve, the conduction velocity in palmar sensory fibres of the median nerve, and the conduction velocity in the H reflex pathway remained unchanged. The amplitude of distal muscle (extensor digitorum brevis) and sensory nerve (median) potentials decreased, while the maximal response of more proximal muscles (soleus) was not significantly modified. The soleus T response quickly decreased, although at the same time the H response was increased in the days following administration of vincristine. Thus the T/H ratio seems to be the only convenient electrophysiological method of evaluating the functional impairment of primary afferent distal segments. These results show that vincristine induces a transitory excitability enhancement of the monosynaptic reflex. It is suggested that the drug may cause an increase in the firing rate in proximal segments of injured Ia fibres. Apart from this phenomenon the electrophysiological results lead to the conclusion that vincristine induces distal axonal degeneration, similar to that in other toxic neuropathies (e.g. acrylamide or n-hexane) where a dying-back process has been clearly demonstrated.
 ...
PMID:Early phase of vincristine neuropathy in man. Electrophysiological evidence for a dying-back phenomenon, with transitory enhancement of spinal transmission of the monosynaptic reflex. 624 89

Membrane potential and 42K, 22Na, 86Rb fluxes were measured in frog muscles immersed in sucrose--sulfate media with cation of one type. For elimination of the internal sodium and chloride ions muscles were preincubated in sucrose solution. It was found that dependence of membrane potential on the cation concentration deviated from the Goldman--Hodgkin--Katz relation. The variation in the permeability coefficients which should be assumed to correlate to experimental dependence with the Goldman--Hodgkin--Katz formula, were estimated. The required values of the permeability, coefficients were shown to differ from those found by fluxes. The influx/efflux rate constants ratio for all of the cations tested did not obey the Ussing criterion for independent passive movement of ion across membrane. It is concluded that the Goldman--Hodgkin--Katz formula cannot be used for a description of passive ion movement in the systems similar to those studied in this work.
 ...
PMID:[Membrane potential, permeability coefficients and the ratio of the influx/efflux rates for alkaline cations across the muscle fiber membrane of the frog in a bi-ionic system]. 630 55

Mortality among 2,113 U.S. and Canadian members of the Pulp, Sulfite, and Paper Workers' Union, 1935 through 1964, was studied using a proportionate mortality analysis. Mortality due to gastric cancer was found to be elevated in all jurisdictions, but only in mills using sulfate or sulfite pulping. An excess of mortality due to kidney cancer was limited to mills in Oregon and Washington. Excesses of deaths due to leukemia, Hodgkin's disease, and lymphosarcoma were observed only in mills in Oregon, Washington, and Wisconsin and the province of Quebec. Based on small numbers, excesses of deaths due to cancers of rectum, pancreas, kidney, and lymphosarcoma were seen primarily among sulfite process workers, while Hodgkin's disease deaths occurred primarily in sulfate (kraft) process workers. These findings suggest that cancer mortality in pulp and paper workers may be related both to pulping process and to tree species processed.
 ...
PMID:Mortality among pulp and paper workers. 650 89

A patient suffering from Hodgkin's disease exhibiting acute allergic reaction to vincristine sulfate with mild to moderate dermatologic and cardiovascular signs is described. The change of therapy to vindesine sulfate led to relief of all symptoms. The therapeutic effectiveness of the altered protocol remained unchanged and no other or amplified side effects appeared.
 ...
PMID:Acute allergic reaction due to vincristine sulfate. A case report. 654 2

Forty-six cases with hematological malignancies were treated with vindesine sulfate (VDS); a new semisynthetic vinca alkaloid. Six cases with ALL, 5 cases CML in blastic crisis, 3 Hodgkin's disease (HD) and 4 non-Hodgkin's lymphoma (NHL) were treated with VDS alone. Five out of 6 cases ALL, 2 out of 5 CML in blastic crisis were induced into partial remission with VDS alone. All of 3 HD, and 4 NHL were induced in complete remission (CR) or partial remission (PR). Out of 5 cases AML in CR who received VDS as the maintenance therapy in combination with cyclophosphamide, 6-MP and prednisone, one case relapsed during the treatment, but other four cases maintained CR for 4 to 24 months. One case of APL in relapse, which was treated with VDS and 6-MP, reinduced into CR after one month. Out of 16 cases with malignant lymphoma treated by combination chemotherapy including VDS, eleven cases entered in CR or PR. Out of four cases in which the disease became refractory to vincristine (VCR) or vinblastine (VLB) clinically, two achieved PR. VDS was administered intravenously with 3 mg/body/week. When undesirable effect such as leucocytopenia was observed, the dose was reduced to 2-2.5 mg/body/week or 3 mg/body/2 weeks or month. Neurotoxicity (i.e. Paresthesia 21.7%), alopecia (21.7%), leucocytopenia (19.6%), constipation (10.9%) and fever (6.5%) were main side effects of VDS. The neurotoxicity of VDS, however, seemed far less intensive than VCR.
 ...
PMID:[Administration of vindesine sulfate for the treatment of malignant hematological tumors]. 676 3


<< Previous 1 2 3 4 5 6 Next >>